Core Insights - Royal Philips has launched the RADIQAL trial, a multicenter, randomized study aimed at evaluating the effectiveness of its new ultra-low X-ray dose technology in reducing radiation exposure during coronary procedures without compromising image quality or procedural performance [1][3][10] Company Overview - Royal Philips is a leading health technology company focused on improving health and well-being through innovation, generating sales of EUR 18 billion in 2024 and employing approximately 67,200 people globally [6] Trial Details - The RADIQAL trial will enroll 824 patients with coronary artery disease across six hospitals in Spain, Czech Republic, Denmark, and the US, with the primary objective of demonstrating reduced radiation doses without affecting the performance of coronary procedures [1][10] - The new technology is designed to reduce X-ray exposure by 50% compared to the lowest settings of the existing ClarityIQ technology integrated into the Azurion image-guided therapy system [3][4] Clinical Importance - Reducing radiation exposure while maintaining or improving image quality is a critical goal in interventional cardiology, especially for patients with high BMI or complex conditions requiring multiple interventions [4]